Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Keyhole Limpet Hemocyanin · KLH

Recombinant protein · Immune activation · developed by Celldex Therapeutics

Phase 2 Most advanced trial (none active)
CLDX Developer
1 Registered trials

What is Keyhole Limpet Hemocyanin?

Keyhole limpet hemocyanin (KLH) is a natural protein isolated from the marine mollusc keyhole limpet, used as an immunogenic carrier protein that increases immune responses to haptens and weak antigens such as idiotype proteins. It is studied in glioblastoma and related brain tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KLH
Drug type
Recombinant protein
Mechanism
Immune activation
Pathways
immune response enhancement
Therapy area
Oncology
Developer
Celldex Therapeutics (CLDX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FV4Y0JO2CX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01498328 Phase 2 Glioblastoma Completed CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Giant Cell GlioblastomaGlioblastomaGlioblastoma With Oligodendroglial ComponentGliosarcomaRecurrent GlioblastomaRelapsed GlioblastomaSmall Cell Glioblastoma

More from Celldex Therapeutics

Barzolvolimab Phase 3 CDX 0158 Phase 1 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-1307 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-585 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Rindopepimut Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind Keyhole Limpet Hemocyanin

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.